Clinical trial endpoints - e-Patient Dave ESMO 2014
-
Upload
e-patient-dave-debronkart -
Category
Health & Medicine
-
view
219 -
download
1
description
Transcript of Clinical trial endpoints - e-Patient Dave ESMO 2014
![Page 1: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/1.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
JAMIA, 1997
“e-Patient Dave” deBronkart Twitter: @ePatientDave
facebook.com / ePatientDave LinkedIn.com / in / ePatientDave
[email protected] Skype: ePatientDave
Meaningful Patient Involvement in
Clinical Trial Endpoints
![Page 2: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/2.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Angela Coulter
![Page 3: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/3.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Paternalistic caring
“No, honey – you don’t know what you need.”
“I’ll take care of you.”
Sensible – up to a point
“I’ll decide for you.”
![Page 4: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/4.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Zoe When does autonomy become appropriate?
![Page 5: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/5.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Empowerment “An empowering approach to participation treats poor people���as co-producers
with authority and control ���over decisions and resources
devolved to the lowest appropriate level.” World Bank’s definition
![Page 6: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/6.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Empowerment “An empowering approach to participation treats poor people���as co-producers
with authority and control ���over decisions and resources
devolved to the lowest ���appropriate level.”
![Page 7: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/7.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Empowerment “An empowering approach to participation treats patients ���as co-producers
with authority and control ���over decisions and resources
devolved to the lowest appropriate level.”
![Page 8: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/8.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Institute of Medicine – Sept 2012 Major New Report: “Best Care at Lower Cost”
![Page 9: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/9.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Yes, the IOM itself says e-patients are an
essential part of tomorrow’s healthcare.
Patient-Clinician Partnerships Engaged, empowered patients— A learning health care system is anchored on patient needs and perspectives and promotes the inclusion of patients, families, and other caregivers as vital members of the continuously learning care team.
![Page 10: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/10.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Who gets to say which outcomes are important??
![Page 11: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/11.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Who gets to say which outcomes should be goals?
![Page 12: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/12.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Who gets to declare which
endpoint we measure?
![Page 13: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/13.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Who gets to say what’s in the patient’s best
interest?
![Page 14: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/14.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Paternalistic caring
“No, honey – you don’t know what you need.”
“I’ll take care of you.”
Sensible – up to a point
“I’ll decide for you.”
![Page 15: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/15.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
I predict a new battlefield:
time versus certainty
![Page 16: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/16.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
To the scientist, the time when we
find the truth is irrelevant to its worth.
![Page 17: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/17.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
But to a patient with a progressive
disease, time is everything
![Page 18: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/18.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Time Value of Money
“A dollar today is worth more
than a dollar next year”
![Page 19: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/19.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Patients are proposing there’s a
Time Value of a Treatment
“A treatment today is worth more than the
same treatment next year”
![Page 20: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/20.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
For patients with a progressive disease …
“A treatment today may be worth more than a better treatment next year”
![Page 21: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/21.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
What factors are worth tracking
as a patient’s condition
and development of a treatment
proceed separately but simultaneously?
![Page 22: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/22.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Factors in an equation for the time value of a treatment
• Efficacy – We assume efficacy will improve as we continue
developing and testing the intervention
• Certainty of the benefit (low p) – More studies, and improvements in development,
should improve certainty over time
• Utility to the patient (need, benefit, etc)
![Page 23: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/23.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Time Value of a Treatment as time progresses:
Vtx,t = f(efficacyt, certaintyt, ut)
![Page 24: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/24.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
Scientists quantify efficacy and certainty.
Only the individual patient can assess the utility.
![Page 25: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/25.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
June 11, 2014
Announced –
• Patient advisory panel
• Patient peer review of research papers
• Authors are to document how they involved patients in defining the question and outcome measures
www.bmj.com/content/348/bmj.g3726
![Page 26: Clinical trial endpoints - e-Patient Dave ESMO 2014](https://reader034.fdocuments.us/reader034/viewer/2022051609/547d1f555806b5ea3f8b4854/html5/thumbnails/26.jpg)
Copyright © 2013 e-Patient Dave Please contact via epatientdave.com before re-using
JAMIA, 1997
“e-Patient Dave” deBronkart Twitter: @ePatientDave
facebook.com / ePatientDave LinkedIn.com / in / ePatientDave
[email protected] Skype: ePatientDave
Meaningful Patient Involvement in
Clinical Trial Endpoints